CVRx price target raised to $20 from $16 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on CVRx (CVRX) to $20 from $16 and keeps an Overweight rating on the shares ...
Boston Scientific price target raised to $115 from $95 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Boston Scientific (BSX) to $115 from $95 and keeps an Overweight rating on ...
Piper Sandler raises Glaukos stock target to $180, keeps overweight
Piper Sandler analyst Matt O'Brien increased the price target for Glaukos Corporation (NYSE:GKOS) shares to $180 from the previous target of $140, while maintaining an Overweight rating on the stock.